Literature DB >> 32672390

Neonatal Candida auris infection: Management and prevention strategies - A single centre experience.

Jayasree Chandramati1, Laleet Sadanandan1, Anil Kumar2, Sasidharan Ponthenkandath1.   

Abstract

AIM: Our aim was to identify the clinical features and outcome of multidrug resistant Candida auris (CA) infection in neonates.
METHODS: This is a retrospective case cohort study of 17 neonates who developed sepsis caused by CA infection in a tertiary care neonatal intensive care unit over 3 years. The risk factors, clinical features, treatment and outcome were studied.
RESULTS: The mean gestation was 32.4 ± 4.9 weeks with overall mortality of 41%. Clinical features were indistinguishable from other causes of sepsis. CA was sensitive to micafungin but resistant to fluconazole and had variable sensitivity to voriconazole and amphotericin. Survival improved to 83% when infants were treated with a combination of micafungin and amphotericin. Non-survivors were of lower birthweights and had other risk factors.
CONCLUSIONS: The management guidelines and infection control measures are described in this largest series of neonatal CA infection. Treatment with a combination of amphotericin and micafungin improved the outcome.
© 2020 Paediatrics and Child Health Division (The Royal Australasian College of Physicians).

Entities:  

Keywords:  Candida auris; late onset sepsis; neonates; outcome

Mesh:

Substances:

Year:  2020        PMID: 32672390     DOI: 10.1111/jpc.15019

Source DB:  PubMed          Journal:  J Paediatr Child Health        ISSN: 1034-4810            Impact factor:   1.954


  1 in total

1.  Evaluating the measures taken to contain a Candida auris outbreak in a tertiary care hospital in South India: an outbreak investigational study.

Authors:  Dipu Thareparambil Sathyapalan; Remya Antony; Vrinda Nampoothiri; Anil Kumar; Nandita Shashindran; Jini James; Jisha Thomas; Preetha Prasanna; Akkulath Sangita Sudhir; Jeslyn Mary Philip; Fabia Edathadathil; Binny Prabhu; Sanjeev Singh; Merlin Moni
Journal:  BMC Infect Dis       Date:  2021-05-06       Impact factor: 3.090

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.